Skip to main content

Lupus

    Lupus Panel
    RT @Yuz6Yusof: #ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE &
    1 year 5 months ago
    #ACR22 Abstr#2068 Data from John Hopkins showed leading cause of deaths (1985-2019) in #lupus were #SLE & Cardiovascular (both 23%), then cancer & infection.SLE deaths common in younger. African-American died younger vs White. Need to improve with therapies we now have @RheumNow https://t.co/4tDhr1Eodm
    RT @Yuz6Yusof: #ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study
    1 year 5 months ago
    #ACR22 Abstr#2061 It's time to tight control newly diagnosed #lupus nephritis patients. In a cohort study which 16% developed advanced CKD, risk was reduced if remission achieved by 12 mths of diagnosis. =>1 flare & shorter time-on-therapy increased risk @RheumNow #ACRBest https://t.co/swYn2g4hqe
    RT @bella_mehta: #SLE mortality in South Carolina Lupus Cohort
    Standardized mortality ratio (SMR) is higher in blacks
    Hi
    1 year 5 months ago
    #SLE mortality in South Carolina Lupus Cohort Standardized mortality ratio (SMR) is higher in blacks Higher SLICC scores in blacks abst#2106 #ACR22 @rheumnow https://t.co/NAdNhUHsbc
    RT @Janetbirdope: New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 m
    1 year 5 months ago
    New SLE Rx. Deucravitinib a TYK2i phase 2 RCT showed SRI4 endpoint. Subset of 3 mg bid was best vs 6 mg bid and 12 mg OD. Skin via CLASI-50 & other endpoints also positive. Awaiting phase III. Abst1117 #ACR22 @RheumNow https://t.co/fZI3AV5pML
    RT @RichardPAConway: Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to bette
    1 year 5 months ago
    Hidekawa et al. HCQ use assoc reduced severe infection in LUNA SLE registry, HR 0.26. ?due to better disease control rather than anti-infectious role, but HR 0.32 in multivariable model including SLEDAI. @RheumNow #ACR22 Abstr#2059 https://t.co/EgTJOAymoF https://t.co/gmchk9ZS5L
    RT @RichardPAConway: Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE
    1 year 5 months ago
    Figueroa Parra @AliDuarteMD et al. Multimorbidity in SLE. Higher at classification - due to non-SLE assoc. SLE-assoc drive increased accumulation over time but non-SLE assoc also increased @RheumNow #ACR22 Abstr#2091 https://t.co/6IyhovSNYA https://t.co/qmYfoqCTtz
    RT @Yuz6Yusof: #ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT
    1 year 5 months ago
    #ACR22 Abstr#2055 SRI-4 and BICLA: how do they converge and diverge? Analyses of 6 x Non-Renal #Lupus RCT showed discordance (12-30%).When discordant, SRI-4 classified more pts as responders vs BICLA. Concordance higher at 52 vs 24 wks. Vital to interpret both outcomes @RheumNow https://t.co/prSfTrv0E8
    RT @Yuz6Yusof: #ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidem
    1 year 5 months ago
    #ACR22 Abstr#1764 In addition to race, what social health aspect to consider when assessing #lupus epidemiology? A study identified urbanicity and area deprivation index were associated with SLE diagnosis. Could those living in the city = better access and diagnosis? @RheumNow https://t.co/PsNt8vQufs
    Urine Proteomics in SLE with Dr. Michelle Petri

    Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarke
    1 year 5 months ago
    Urine Proteomics in SLE with Dr. Michelle Petri Dr. Michelle Petri discusses abstract 0536, Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria, being presented Saturday at #ACR22. https://t.co/rBDnbSqQCI https://t.co/WfERf1k5VB